MaxCyte (MXCT) vs. Its Peers Head-To-Head Contrast

MaxCyte (NASDAQ:MXCTGet Rating) is one of 39 public companies in the “Commercial physical research” industry, but how does it contrast to its competitors? We will compare MaxCyte to similar companies based on the strength of its valuation, analyst recommendations, institutional ownership, earnings, risk, dividends and profitability.

Analyst Recommendations

This is a breakdown of current ratings and target prices for MaxCyte and its competitors, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MaxCyte 0 0 5 0 3.00
MaxCyte Competitors 105 767 1305 30 2.57

As a group, “Commercial physical research” companies have a potential upside of 52.75%. Given MaxCyte’s competitors higher probable upside, analysts plainly believe MaxCyte has less favorable growth aspects than its competitors.

Profitability

This table compares MaxCyte and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
MaxCyte -41.15% -7.39% -6.78%
MaxCyte Competitors -260.35% -8.17% -2.92%

Earnings and Valuation

This table compares MaxCyte and its competitors gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
MaxCyte $33.89 million -$19.08 million -25.94
MaxCyte Competitors $2.80 billion $101.15 million 13.08

MaxCyte’s competitors have higher revenue and earnings than MaxCyte. MaxCyte is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Institutional and Insider Ownership

65.9% of MaxCyte shares are owned by institutional investors. Comparatively, 59.5% of shares of all “Commercial physical research” companies are owned by institutional investors. 5.4% of MaxCyte shares are owned by insiders. Comparatively, 11.4% of shares of all “Commercial physical research” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

MaxCyte competitors beat MaxCyte on 7 of the 12 factors compared.

About MaxCyte (Get Rating)

MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Receive News & Ratings for MaxCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte and related companies with MarketBeat.com's FREE daily email newsletter.